American CryoStem Announces e –

EATONTOWN, NJ / ACCESSWIRE / November 23, 2021 / American CryoStem Corporation (OTC PINK: CRYO), a leading clinical-stage biotechnology developer of adipose tissue-based cellular technologies for regenerative and personalized medicine, today announced that it has added John “Jay” Schwartz, PhD to its Scientific Advisory Board and medical.

Dr Schwartz, with a doctorate in biochemistry and molecular biology, was an academic researcher at Harvard and MIT for more than 10 years. He is an accomplished life science entrepreneur, business mentor, consultant and investor with a demonstrated track record in identifying and leading commercially viable and start-up businesses, conceptualization and initial funding of the bench. clinical development and discharge. More than 30 years of Dr. Schwartz entrepreneurship spanned the technical development and commercialization of drugs, medical devices, combination products and diagnostics; regulatory approval, orphan drug / expedited approval, clinical reimbursement, as well as intellectual property strategies.

Dr. Schwartz’s business development experience includes negotiating and concluding several collaborative development, procurement and licensing agreements. Most recently, he led AcuityBio Corporation to a successful acquisition by Cook Biotech. During his career, he led and advised several companies towards successful exits via acquisitions in deals ranging from 35 to 500 million dollars. Over the past 21 years, through his connections with the MIT Venture Mentoring Service and as an Assistant Instructor in the National Science Foundation’s ICorps program, he has mentored numerous life science and technology companies.

John Arnone, CEO of American CryoStem Corporation, commented, “The arrival of Dr. Schwartz, a seasoned biotechnology executive and successful entrepreneur, will accelerate the next evolution of the company’s strategy leading to multiple successful biologic license applications. Dr. Schwartz will bring critical expertise and proven executive leadership to our mission to develop a world-class pipeline portfolio. “

Dr. Schwartz said, “I am very impressed with American CryoStem’s robust, scalable and reproducible stem cell technology platform that overcomes the historical technical and commercial constraints that have hampered advancements in this industry. I am proud to join my academic and clinical colleagues on this advisory board and look forward to the work ahead to build a high-value pipeline for medicine, stem cells and regenerative medicine therapies to transform the life of patients with serious illnesses. “

For more information, please visit:, send email to: [email protected] or contact the Company directly at 732-747-1007.

About American CryoStem Corporation: (CRYO), founded in 2008, is a clinical-stage biotechnology company, which develops and delivers autologous mesenchymal stem cell (MSC) therapies based on its patented “mCMC” mesenchymal chemistry cell platform , manufacturing and controls. The platform supports a growing pipeline of therapies, biological products and processes, collaborative development opportunities, clinical and international licensing opportunities. The company’s platform offers patients the ability to process, store and use a single harvest of adipose tissue (fat) for cosmetic fat transfer and / or processing to MSCs. The platform is configured to produce large quantities of genetically adapted mesenchymal stem cells (ATCELLMT) for future individual or multiple successive treatments as needed, “on demand”. The Company has strategically positioned its cell therapy product portfolio for; attract collaborative partners, accelerate the creation of new processing applications, and improve manufacturing processes and testing methods. Each new therapeutic indication is designed to give rise to additional intellectual property and targeted commercial products in order to generate significant future revenues over time. CRYO targets incurable and incurable neurological diseases, disorders and conditions that have high unmet medical need and orphan drug designation from the US FDA. The Company operates a cGMP compliant and FDA registered laboratory located in Monmouth Junction, New Jersey, United States, and licensed laboratory operations in Hong Kong, China and Thailand.

THE SOURCE: American company CryoStem

See the source version on

Comments are closed.